Indicated for the treatment of adult patients with: 🔹 ALK-positive NSCLC: Advanced or metastatic Non-Small Cell Lung Cancer that is ALK-positive (detected by an FDA-approved test). 🔹 Usage: First-line treatment or for patients who have progressed on crizotinib.

Dosage and administration

Packaging: 150 mg capsules. ⚠️ ADMINISTRATION PROTOCOL: Recommended Dose: 600 mg orally twice daily. Pill Count: Take 4 capsules (150 mg each) twice a day (morning and evening). Food Intake: Must be taken with food to ensure proper absorption. Administration: Swallow capsules whole. Do not open or dissolve. Supply Note: One pack of 56 capsules lasts for 7 days at the standard dosage.

Hypersensitivity to Alectinib. Pregnancy and breastfeeding (embryo-fetal toxicity). Severe hepatic impairment (precaution required).

Common adverse reactions include: 🩸 Cardiovascular/Muscular: Bradycardia (slow heart rate), myalgia (muscle pain), increased CPK levels. 📉 Gastrointestinal: Constipation (very common), nausea, hyperbilirubinemia. 🌀 Physical: Edema (swelling of hands, feet, or eyes), photosensitivity (sunburn propensity). ⚠️ Warning: Patients should use sunscreen and avoid prolonged sun exposure during treatment.

Alecnib — Alectinib 150 mg, 56 pcs, Everest

100% original product

Active ingredient

Alectinib

Manufacturer

Everest

Dosage 150 mg

Dosage form Capsules

Capsules per pack 56

Alecnib (Alectinib) Capsules

Name: Alecnib
Brand: Everest
SKU: PROD-146
Price: 19777 UAH
Availability: InStock

19777₴ ~~21096₴~~ -6%

Alecnib 150 mg (Alectinib) is a highly selective second-generation ALK (anaplastic lymphoma kinase) inhibitor.

Manufacturer: Everest Pharmaceuticals. Each pack contains 56 capsules. It targets and blocks the ALK protein in cancer cells. It is particularly noted for its systemic activity and efficacy against brain metastases.

Key Feature:

Standard of care for ALK-positive lung cancer due to its ability to cross the blood-brain barrier and prolonged progression-free survival.

Indicated for the treatment of adult patients with:

🔹 ALK-positive NSCLC: Advanced or metastatic Non-Small Cell Lung Cancer that is ALK-positive (detected by an FDA-approved test).
🔹 Usage: First-line treatment or for patients who have progressed on crizotinib.

Packaging: 150 mg capsules.

⚠️ ADMINISTRATION PROTOCOL:

Recommended Dose: 600 mg orally twice daily.
Pill Count: Take 4 capsules (150 mg each) twice a day (morning and evening).
Food Intake: Must be taken with food to ensure proper absorption.
Administration: Swallow capsules whole. Do not open or dissolve.
Supply Note: One pack of 56 capsules lasts for 7 days at the standard dosage.

Hypersensitivity to Alectinib.
Pregnancy and breastfeeding (embryo-fetal toxicity).
Severe hepatic impairment (precaution required).

Common adverse reactions include:

🩸 Cardiovascular/Muscular: Bradycardia (slow heart rate), myalgia (muscle pain), increased CPK levels.
📉 Gastrointestinal: Constipation (very common), nausea, hyperbilirubinemia.
🌀 Physical: Edema (swelling of hands, feet, or eyes), photosensitivity (sunburn propensity).
⚠️ Warning: Patients should use sunscreen and avoid prolonged sun exposure during treatment.

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 14.03.2026

Active ingredient

Alectinib

Manufacturer

Everest

Dosage 150 mg

Dosage form Capsules

Capsules per pack 56

100% original product

Delivery across Ukraine

Customer reviews

What Customers Say

No reviews yet

Your review can be the first!

Alecnib (Alectinib) Capsules

What Customers Say

No reviews yet

Contact us

Request a call